Researchers at Massachusetts Eye and Ear/Harvard Medical School and Boston University have successfully shown neuroprotection in a Parkinson’s mouse model using new techniques to deliver drugs across the naturally impenetrable blood-brain barrier. Their findings, published in Neurosurgery, lend hope to patients around the world with neurological conditions that are difficult to treat due to a barrier mechanism that prevents approximately 98 percent of drugs from reaching the brain and central nervous system.
“We are developing a platform that may eventually be used to deliver a variety of drugs to the brain,” said senior author Benjamin S. Bleier, M.D. (in photo), of the department of otolaryngology at Mass. Eye and Ear/Harvard Medical School. “Although we are currently looking at neurodegenerative disease, there is potential for the technology to be expanded to psychiatric diseases, chronic pain, seizure disorders and many other conditions affecting the brain and nervous system down the road.”
Using nasal mucosal grafting, researchers delivered glial derived neurotrophic factor (GDNF), a therapeutic protein in testing for treating Parkinson’s disease, to the brains of mice. They showed through behavioral and histological data capture that their delivery method was equivalent to direct injection of GDNF – the current gold standard for delivering this drug in Parkinson’s disease despite its traumatic nature and high complication rates – in diffusing drugs to the brain.
The researchers chose to test their delivery method with GDNF because the therapy has been shown to delay and even reverse disease progression of Parkinson’s disease in pre-clinical models. The study was funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
“Brain diseases are notoriously difficult to treat due to the natural protections the body builds against intrusion,” said Jamie Eberling, Ph.D., senior associate director of MJFF research programs. “Dr. Bleier’s group has identified a potential avenue to pass that barrier, and we look forward to the next stage of research to further test its utility in people with Parkinson’s disease .”
Nasal mucosal grafting is a technique regularly used in the ENT field to reconstruct the barrier around the brain after surgery to the skull base. ENT surgeons commonly use endoscopic approaches to remove brain tumors through the nose by making a window through the blood-brain barrier to access the brain. Once they have finished the treatment, they use adjacent nasal lining to rebuild the hole in a permanent and safe way. The safety and efficacy of these methods have been well established through long-term clinical outcomes studies in the field, with the nasal lining protecting the brain from infection just as the blood brain barrier has done.
Dr. Bleier saw an opportunity to apply these techniques to the widespread clinical dilemma of delivering drugs across the barrier to the brain and central nervous system. By functionally replacing a section of the blood-brain barrier with nasal mucosa, which is more than 1,000 times more permeable than the native barrier, surgeons may create a “screen door” to allow for drug delivery to the brain and central nervous system.
The technique has the potential to benefit a large population of patients with neurodegenerative disorders, where there remains a specific unmet need for blood-brain penetrating therapeutic delivery strategies.
“We see this expanding beyond Parkinson’s disease, as there are multiple diseases of the brain that do not have good therapeutic options,” Dr. Bleier said. “It is a platform that opens doors for new discovery and could enable drug development for an underserved population.”
The Latest on: neurodegenerative disorders
[google_news title=”” keyword=”neurodegenerative disorders” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: neurodegenerative disorders
- Brain Autopsies Reveal a Potential New Culprit Behind Alzheimer's Diseaseon April 30, 2024 at 6:50 pm
Analysis of human brain tissue revealed differences in how immune cells behave in brains with Alzheimer's disease compared to healthy brains, indicating a potential new treatment target. University of ...
- Promising new study with diabetes drug for people with Parkinson's diseaseon April 30, 2024 at 12:16 pm
April is Parkinson's Disease awareness month, and there is a new drug that has promising results for people with Parkinson's. GLP-1 agonist drugs like Ozempic and Wegovy are extremely popular, ...
- Ionis Pharmaceuticals gets grant for modified oligonucleotide for reducing lRRK2 rna in neurodegenerative diseaseson April 30, 2024 at 5:47 am
Discover how Ionis Pharmaceuticals' patent for modified oligonucleotides offers hope in treating Parkinson's disease by reducing LRRK2 levels and alleviating symptoms. Explore the groundbreaking ...
- NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Diseaseon April 29, 2024 at 6:59 am
NKGen advances its neurodegenerative disease program with FDA IND clearance for its Phase 1/2a SNK01 Clinical Trial in patients with Parkinson’s ...
- Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxiaon April 29, 2024 at 4:54 am
New Evidence Indicates ATH434 can Function as an Iron Chaperone to Redistribute Iron –MELBOURNE, Australia and SAN FRANCISCO, April 29, ...
- Ley ELA: What is Spain's new neurodegenerative disorders law?on April 29, 2024 at 3:23 am
Spain's new 'ALS Law' has been expanded to include all other neurodegenerative disorders such as Alzheimer's, Parkinson's and Huntington's. Here's what you need to know.
- Synthetic nanomaterial could be an effective tool for treating neurodegenerative diseaseson April 26, 2024 at 1:44 am
A newly developed nanomaterial that mimics the behavior of proteins could be an effective tool for treating Alzheimer's and other neurodegenerative diseases.
- Contaminated deer meat may have caused 2 hunters' deadly brain diseaseson April 25, 2024 at 11:28 am
A new report calls for further study into a possible link between chronic wasting disease in deer and a rare and deadly brain disease in humans.
- Mitochondrial Meltdown: The Energy Failure Behind Neurodegenerative Diseaseson April 21, 2024 at 2:21 am
Key pathway identified for how depletion of axonal mitochondria disrupts autophagy. Researchers from Tokyo Metropolitan University have identified how proteins collect abnormally in neurons, a feature ...
- Battle against fatal neurodegenerative disease advances on two frontson April 19, 2024 at 11:13 am
Given no more than five years to live, Blais set about ticking off his final bucket-list challenge: the annual "Ironman World Championship" in the US state of Hawaii. In October 2005, six months after ...
via Bing News